Fig. 1 contains an error. The correct rule-in cut-off of NAFLD Fibrosis Score indicating patients at intermediate-high risk of advanced fibrosis should read ≥−1.455. The correct figure is reported below. The authors apologise for the mistake.
Appendix. Members of the guidelines panel
Coordinator: Giulio Marchesini; AISF Members: Elisabetta Bugianesi, Patrizia Burra, Fabio Marra, Luca Miele, Anna Alisi, Piero Vajro, Mario Masarone, Salvatore Petta, Marcello Persico, Gianluca Svegliati-Baroni, Luca Valenti; SID Members: Massimo Federici, Francesco Purrello, Ferdinando Carlo Sasso, Giovanni Targher; SIO Members: Luca Busetto, Maria Letizia Petroni, Ferruccio Santini; Metodologists: Calogero Cammà, Agostino Colli.
Article info
Publication history
Published online: February 13, 2023
Footnotes
☆This corrigendum is co-published in the journals: Digestive and Liver Disease https://doi.org/10.1016/j.dld.2023.01.152; Nutrition, Metabolism & Cardiovascular Diseases https://doi.org/10.1016/j.numecd.2023.01.010 and Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity https://doi.org/10.1007/s40519-023-01543-6.DOI of original article: https://doi.org/10.1016/j.dld.2021.04.029.
Identification
Copyright
© 2021 The Author(s). Published by Elsevier Ltd on behalf of Editrice Gastroenterologica Italiana S.r.l. All rights reserved.
ScienceDirect
Access this article on ScienceDirectLinked Article
- Non-alcoholic fatty liver disease in adults 2021: A clinical practice guideline of the Italian Association for the Study of the Liver (AISF), the Italian Society of Diabetology (SID) and the Italian Society of Obesity (SIO)Digestive and Liver DiseaseVol. 54Issue 2
- PreviewNonalcoholic fatty liver disease (NAFLD) is a common and emerging liver disease in adults, paralleling the epidemic of obesity and diabetes, and leading to worrisome events (hepatocellular carcinoma and end-stage liver disease). In the last years, mounting evidence added insights about epidemiology, natural history, diagnosis and lifestyle-based or drug treatment of NAFLD. In this rapidly evolving scenario, members of the Associazione Italiana per lo Studio del Fegato (AISF), the Società Italiana di Diabetologia (SID) and the Società Italiana dell'Obesità (SIO) reviewed current knowledge on NAFLD.
- Full-Text
- Preview
